Zobrazeno 1 - 7
of 7
pro vyhledávání: '"R-CVP Regimen"'
Autor:
Alison Walker, Bhavana Bhatnagar, Gregory K. Behbehani, Nicole Grieselhuber, Caner Saygin, Karilyn Larkin, John C. Byrd, Sumithira Vasu, Meixiao Long, James S. Blachly, Alice S. Mims
Publikováno v:
Leukemia research. 89
R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma
Autor:
Anne Besançon, Andreaa Anghel, Habib Ghnaya, Delphine Bolle, Jeremy Sandrini, Alix Baugier de Materre, Jonathan Farhi, Catherine Truong, Nathalie Denizon, Kamel Laribi
Publikováno v:
Annals of Hematology
Annals of Hematology, Springer Verlag, 2016, ⟨10.1007/s00277-016-2768-x⟩
Annals of Hematology, Springer Verlag, 2016, ⟨10.1007/s00277-016-2768-x⟩
International audience; Patients aged 80 or over with diffuse large B cell lymphoma (DLBCL) often have comorbidities that increase drug toxicity and prevent the use of otherwise optimal treatment. We performed a retrospective analysis of 43 patients
Publikováno v:
Research Journal of Pharmacy and Technology. 10:1645
Immunosuppressive chemotherapy can lead to Hepatitis B virus reactivation resulting in Hepatitis. Previous history of HBV infection is a major risk factor. Here we report a 66 yr old male, with Follicular lymphoma stage 4. He was planned for B-R (Ben
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michael Crump, Erik Vandendries, Toshiki Uchida, Catherine Thieblemont, Yukio Kobayashi, David MacDonald, Andrew Davies, Kiyohiko Hatake, Michinori Ogura, Randeep Sangha, Steven Y. Hua, Kensei Tobinai, Luisa Paccagnella, Taro Ishibashi
Publikováno v:
Blood. 118:3715-3715
Abstract 3715 Background: Inotuzumab ozogamicin (INO) is a humanized anti-CD22 antibody conjugated to calicheamicin, a potent antitumor antibiotic. CD22 is expressed on the majority of B-cell non-Hodgkin lymphomas (NHL). Although safety and prelimina
Autor:
Yuko Mishima, Yasuhito Terui, Daisuke Ennishi, Masahiro Yokoyama, Kiyohiko Hatake, Tomohiro Myojo, Kengo Takeuchi, Shunji Takahashi
Publikováno v:
Blood. 108:4715-4715
Introduction: MALT lymphoma, even if advanced stage, is known to have indolent outcome. However, previous reports showed that chemotherapy only could not improve the disease progression. Recently a few reports demonstrated rituximab monotherapy could
Autor:
A. Majid Shojania
Publikováno v:
Blood. 108:4618-4618
A Caucasian female, born in 1941, was first seen in November 2002 because of tiredness, weight loss and splenomegaly. She was taking glyburide, procylidine and venlafaxine for diabetes, parkinsonism and depression. Physical examination, revealed mark